Plain-English translation of NCT07093073 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer treatment called U01 (ssCAR-19), which is a type of cell therapy designed to fight B-cell lymphoma — a blood cancer. The treatment works by taking your own immune cells, engineering them in a laboratory to recognize and attack cancer cells, and then putting them back into your body. This version includes a special modification to help reduce side effects.
Many people with B-cell lymphoma eventually stop responding to standard chemotherapy, and their cancer comes back or gets worse. This trial exists to see if this new cell therapy can help patients whose cancer is no longer responding to conventional treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, doctors will collect your immune cells through a procedure similar to donating blood plasma (called leukapheresis). Your cells will be sent to a laboratory where they are engineered for about 2–4 weeks. Once ready, you will receive the modified cells back through an infusion, similar to a blood transfusion. You will then have frequent follow-up visits and blood tests to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Enrollment target
~30 participants
Started
January 2025
Primary completion
January 2027
Age range
2 Years – 75 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenjun Zhang, Ph.D
Tongji Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.